Core Viewpoint - The company has developed an upgraded 20-valent pneumococcal conjugate vaccine based on the existing 13-valent vaccine, which has received approval for clinical trials from the National Medical Products Administration [1][4]. Group 1: Vaccine Development - The new 20-valent pneumococcal conjugate vaccine includes 7 additional serotypes, covering a total of 20 serotypes that are currently prevalent, aimed at preventing invasive diseases such as pneumonia, meningitis, and bacteremia [3]. - The vaccine is intended for administration to individuals aged 2 months and older, targeting infections caused by the 20 serotypes included in the vaccine [3]. Group 2: Public Health Significance - Pneumococcal diseases are a significant global public health issue, being a major cause of morbidity and mortality among children and adults in China [2]. - The World Health Organization (WHO) classifies pneumococcal diseases as requiring "extremely high priority" for vaccine prevention, highlighting the urgent need for effective vaccination strategies [2]. Group 3: Market Position and Future Plans - The approval of the 20-valent vaccine for clinical trials enhances the company's pipeline in the pneumococcal vaccine sector, indicating a commitment to addressing unmet clinical needs in core disease areas [4]. - The company aims to continue advancing innovative vaccine development to improve its innovation capabilities, core competitiveness, and overall strength in the market [4].

Core Viewpoint - The company has developed an upgraded 20-valent pneumococcal conjugate vaccine based on the existing 13-valent vaccine, which has received approval for clinical trials from the National Medical Products Administration [1][4]. Group 1: Vaccine Development - The new 20-valent pneumococcal conjugate vaccine includes 7 additional serotypes, covering a total of 20 serotypes that are currently prevalent, aimed at preventing invasive diseases such as pneumonia, meningitis, and bacteremia [3]. - The vaccine is intended for administration to individuals aged 2 months and older, targeting infections caused by the 20 serotypes included in the vaccine [3]. Group 2: Public Health Significance - Pneumococcal diseases are a significant global public health issue, being a major cause of morbidity and mortality among children and adults in China [2]. - The World Health Organization (WHO) classifies pneumococcal diseases as requiring "extremely high priority" for vaccine prevention, highlighting the urgent need for effective vaccination strategies [2]. Group 3: Market Position and Future Plans - The approval of the 20-valent vaccine for clinical trials enhances the company's pipeline in the pneumococcal vaccine sector, indicating a commitment to addressing unmet clinical needs in core disease areas [4]. - The company aims to continue advancing innovative vaccine development to improve its innovation capabilities, core competitiveness, and overall strength in the market [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 – 1 – 全 部 位 於 非 洲 和 亞 洲，佔 全 球 總 病 例 數 的66%，而 中 國 位 列 第 二，佔 全 球 總病例數的12%。WHO對 可 用 疫 苗 預 防 的 疾 病 的 分 級 中，將 肺 炎 球 菌 性 疾 病 定 為 需「極 高 度 優 先」使 用 疫 苗 預 防 的 疾 病。 AIM Vaccine Co., Ltd. 艾美疫苗股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：06660） 自願性公告 20價肺炎球菌多糖結合疫苗 獲批開展臨床試驗 本 公 告 由 艾 美 疫 苗 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）自 願 作 出，以 告 知 本 公 司 股 東 及 潛 在 投 資 者 本 集 團 ...

Core Viewpoint - The announcement highlights the successful completion of Phase III clinical trials for the company's high-titer human diploid rabies vaccine, marking a significant step towards commercialization and establishing a solid foundation for future market entry [1][2]. Group 1: Product Development and Innovation - The new high-titer human diploid rabies vaccine represents a major technological upgrade in the rabies vaccine field, demonstrating significantly higher efficacy compared to existing human diploid vaccines under the same dosage conditions [1][2]. - The company has overcome traditional production challenges related to low virus titer and yield through optimized purification processes, enhancing product quality and safety [2]. - The vaccine utilizes human diploid cells instead of Vero cells, providing a natural safety advantage and aligning with WHO recommendations as the gold standard for rabies vaccines [3]. Group 2: Market Potential and Competitive Advantage - China is projected to become the largest rabies vaccine market globally, with an estimated market value of 14.8 billion yuan by 2030, driven by product updates and increased vaccination rates [2]. - The new vaccine offers flexible administration methods, including the "five-dose method," "simple four-dose method," and "2-1-1 four-dose method," making it more convenient for healthcare providers [2]. - The company aims to solidify its position as the second-largest supplier of rabies vaccines globally, enhancing its competitive edge and contributing to sustainable growth through a diversified product portfolio [3].

狂犬病是世界上致死率最高的疾病，一旦发病，致死率接近100%。目前，在临床上缺乏治疗狂犬病的 有效方法，因此暴露后的预防至关重要，主要预防措施是接种人用狂犬病疫苗。与传统的Vero细胞狂犬 疫苗相比，人二倍体狂犬疫苗使用了人二倍体细胞代替了Vero细胞，该细胞与人同源，具有天然的安全 性优势。目前市场上的人二倍体狂犬疫苗与Vero细胞狂犬疫苗相比，价格高出3到5倍，具有更高的产品 附加值。 与传统的初代人二倍体狂犬疫苗相比，集团研发的迭代工艺高效价人二倍体狂犬疫苗，率先突破了传统 工艺中病毒滴度低、产量低的技术瓶颈，在纯化工艺上进行了优化创新，在产品质量和安全性方面均得 到显着提高。这不仅是公司研发实力的体现，也是全球狂犬疫苗高效价工艺领域的重大突破。 中国是全球最大的狂犬疫苗市场，根据灼识咨询统计，在产品更新迭代、狂犬疫苗普及度提高的推动 下，预计于2030年达148亿元。与传统的狂犬疫苗接种针次相比，集团研发的该款产品在接种方式上既 可采用"五针法"接种，也可采用"简易四针法"以及"2-1-1四针法"接种，更加灵活方便。根据国家疾控局 和国家卫健委制定的《狂犬病暴露预防处置工作规范(2023年版)》，要求 ...

Core Viewpoint - The announcement by Ai Mei Vaccine (06660.HK) indicates the successful completion of Phase III clinical trials for its high-efficacy human diploid rabies vaccine, marking a significant step towards commercialization [1] Group 1: Product Development - The new human diploid rabies vaccine features a significantly higher efficacy compared to existing products on the market, representing a major technological upgrade in the rabies vaccine field [1] - Animal trials have shown that the vaccine generates a high level of protective antibodies, outperforming currently available human diploid rabies vaccines under the same dosage conditions [1] Group 2: Market Position and Strategy - The World Health Organization (WHO) recommends human diploid rabies vaccines as the gold standard, and the company is positioned as the second-largest supplier of rabies vaccines globally [1] - The company aims to lead the technological upgrade in the rabies vaccine market, providing higher quality and safer vaccine products, thereby reinforcing its leading position and promoting sustainable development [1] Group 3: Future Prospects - The approval of this new product is expected to enhance the company's product portfolio, creating synergies with existing rabies vaccine series and strengthening its core competitiveness [1] - As part of its global strategy, the new vaccine is anticipated to contribute additional revenue and solidify the company's market position, providing new momentum for sustained and stable growth [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 AIM Vaccine Co., Ltd. 艾美疫苗股份有限公司 本 公 告 由 艾 美 疫 苗 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）自 願 作 出，以 告 知 本 公 司 股 東 及 潛 在 投 資 者 本 集 團 的 最 新 業 務 發 展。 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：06660） 自願性公告 本 集 團 研 發 的 迭 代 工 藝 高 效 價 人 二 倍 體 狂 犬 疫 苗，目 前III期臨床現場工 作 已 順 利 完 成。這 標 誌 著 該 疫 苗 正 式 進 入 新 的 階 段，為 未 來 商 業 化 上 市 奠 定 堅 實 的 基 礎。 該 產 品 是 一 款 迭 代 升 級 的 人 二 倍 體 狂 犬 ...

FF301 致：香港交易及結算所有限公司 公司名稱: 艾美疫苗股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06660 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 507,673,711 | RMB | | 1 | RMB | | 507,673,711 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 507,673,711 | RMB | | 1 | RMB | | 507,673,711 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 ( ...

艾美疫苗(06660)发布公告，黄沛翘女士(黄女士)已提呈辞任本公司联席公司秘书(联席公司秘书)，自 2025年12月31日起生效。 另一位联席公司秘书刘灵女士(刘女士)近期已获联交所确认，其符合联交所证券上市规则(上市规则)第 3.28条规定担任本公司公司秘书的资格，故无需进一步豁免。于黄女士辞任后，刘女士将继续留任并担 任本公司唯一公司秘书，自2025年12月31日起生效。 黄女士于辞任联席公司秘书后，亦已根据上市规则第3.05条的规定辞任本公司授权代表(授权代表)。董 事会宣布，刘女士已获委任为授权代表，以接替黄女士，自2025年12月31日起生效。执行董事周延先生 将继续担任另一授权代表。 ...

Group 1 - The company announced the resignation of Ms. Huang Peiqiao as a co-secretary, effective from December 31, 2025 [1] - Ms. Liu Ling has been confirmed by the Stock Exchange to meet the qualifications to serve as the company secretary, thus no further exemption is required [1] - Following Ms. Huang's resignation, Ms. Liu will continue as the sole company secretary starting from December 31, 2025 [1] Group 2 - Ms. Huang has also resigned as the authorized representative according to the listing rules, effective from the same date [1] - The board has appointed Ms. Liu as the authorized representative to replace Ms. Huang, effective from December 31, 2025 [1] - Executive Director Mr. Zhou Yan will continue to serve as another authorized representative [1]